Objective. MicroRNA-182 miR-182 exhibits altered expression in various cancers. The aim of this study was to investigate the predictive value of miR-182 expression for cancer patient survival. Methods. Eligible studies were identified through multiple search strategies, and the hazard ratios HRs for patient outcomes were extracted and estimated. A meta-analysis was performed to evaluate the prognostic value of miR-182. Results. In total, 14 studies were included. A high miR-182 expression level predicted a worse outcome with a pooled HR of 2.18 95% CI: 1.53–3.11 in ten studies related to overall survival OS, especially in Chinese populations. The results of seven studies evaluating disease-free survival-relapse-free survival-recurrence-free interval-disease-specific survival DFS-RFS-RFI-DSS produced a pooled HR of 1.77 95% CI: 0.91–3.43, which was not statistically significant; however, the trend was positive. When disregarding the DSS from one study, the expression of miR-182 was significantly correlated with DFS-RFS-RFI pooled HR = 2.52, 95% CI: 1.67–3.79. Conclusions. High miR-182 expression is associated with poor OS and DFS-RFS-RFI in some types of cancers, and miR-182 may be a useful prognostic biomarker for predicting cancer prognosis. However, given the current insufficient relevant data, further clinical studies are needed.